CARSON CITY, Nev., Dec. 30 Niusule BiotechCorp., a Nevada corporation formed on April 8, 2008, announced today that itsshares of common stock will begin trading on the OTC Bulletin Board under thesymbol "NIUS" on December 30th, 2008.
For a NIUS quote, visit: http://finance.yahoo.com/q?s=NIUS.OB
"Our main business will be operated in China through our subsidiaryZhejiang Baitai Bioengineering Corp by manufacturing and sellingbiopharmaceutical and health food," said Qinghua Hu, Chairman of NiusuleBiotech Corp. "We believe our public listing is a signal of Niusule BiotechCorp.'s maturity as a company. I would like to thank Niusule Biotech Corp.'spartners, employees and shareholders for their respective roles incontributing to our success."
In a meeting with employees, directors, and shareholders, Hu discussedNiusule Biotech Corp. goals and priorities as a publicly traded entityincluding:
"As we are in our initial stages of growth, we provide both small andinstitutional investors opportunities to invest in China's health foodindustry," said Hu. "The move to the OTC Bulletin Board positions the companyto benefit from greater visibility and liquidity."
About Niusule Biotech Corp.
Founded in 2008, Niusule Biotech Corp.'s main business will be operated inChina through our subsidiary Zhejiang Baitai Bioengineering Corp. NiusuleBiotech Corp. is trying to build a bridge between the USA and China in thehealth food industry and bioengineering industry by accessing the talent poolsin both countries and by applying the mature technologies and high qualitystandards of the USA to its business model in China.
For more information about Niusule Biotech Corp., visithttp://www.niusule.com.
This news release contains forward-looking statements. The companyundertakes no obligation to publicly update or revise any forward-lookingstatements, whether because of new information, future events, or otherwise.Forward-looking statements are inherently subject to risks and uncertainties,some of which cannot be predicted, or quantified. Future events and actualresults could differ materially from those set forth in, contemplated by, orunderlying the forward-looking statements. The risks and uncertainties towhich forward-looking statements are subject include, but are not limited to,the effect of government regulation, competition and other material risksdescribed in the company's filings with the SEC.-- Build long-term value for shareholders by implementing our business plan; -- Seek cooperation and alliance with US companies manufacturing health food products for either distribution or production rights in China; and -- Commitment to being a leading player in China's health food industry and bioengineering industry.
SOURCE Niusule Biotech Corp.